Oncology & Cancer

Low-dose sorafenib may improve therapy for head and neck cancer

Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers ...

Oncology & Cancer

Three 'targeted' cancer drugs raise risk of fatal side effects

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...

Oncology & Cancer

Possible new therapy for the treatment of myeloma

(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...

page 1 from 4